GC
TEVA icon

Grimes & Company’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Grimes & Company’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-48,173
Closed -$1.6M – 217
2017
Q2 		$1.6M Sell
48,173
-1,707
-3% -$52.8K 0.18% 92
2017
Q1 		$1.6M Buy
49,880
+10,692
+27% +$365K 0.18% 91
2016
Q4 		$1.42M Sell
39,188
-683
-2% -$27.3K 0.16% 95
2016
Q3 		$1.83M Sell
39,871
-3,653
-8% -$191K 0.25% 85
2016
Q2 		$2.19M Sell
43,524
-10,361
-19% -$552K 0.29% 83
2016
Q1 		$2.88M Buy
53,885
+7,111
+15% +$417K 0.37% 70
2015
Q4 		$3.07M Sell
46,774
-64
-0.1% -$3.96K 0.41% 67
2015
Q3 		$2.65M Sell
46,838
-2,551
-5% -$165K 0.34% 74
2015
Q2 		$2.92M Buy
49,389
+478
+1% +$29.5K 0.41% 72
2015
Q1 		$3.05M Buy
48,911
+1,139
+2% +$66.2K 0.73% 58
2014
Q4 		$2.75M Sell
47,772
-2,174
-4% -$121K 0.71% 61
2014
Q3 		$2.68M Sell
49,946
-1,182
-2% -$62.6K 0.7% 61
2014
Q2 		$2.68M Buy
51,128
+969
+2% +$49.5K 0.7% 60
2014
Q1 		$2.65M Buy
50,159
+1,374
+3% +$63.5K 0.74% 55
2013
Q4 		$1.96M Sell
48,785
-71,823
-60% -$2.83M 0.58% 60
2013
Q3 		$4.56M Buy
120,608
+8,575
+8% +$335K 1.54% 30
2013
Q2 		$4.39M Buy
+112,033
New +$4.36M 1.6% 26

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Grimes & Company's TEVA Position: Q3 2017 in Review

Grimes & Company sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2017, closing a stake of 48,173 shares — an estimated $1.6M sold.

Grimes & Company first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $4.56M in Q3 2013. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Grimes & Company reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2017 after selling out during the quarter.
  • Grimes & Company sold 48,173 Teva Pharmaceutical Industries Limited shares in Q3 2017, an estimated $1.6M.
  • Grimes & Company first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and held it in 17 quarters.
  • Grimes & Company's Teva Pharmaceutical Industries Limited position peaked at $4.56M in Q3 2013.
  • 537 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2017.

Based on Grimes & Company's 13F filing for Q3 2017, filed 3 Nov 2017.